Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 12,580.70 +125.86 1.01%
S&P 500 1,332.42 +14.60 1.11%
Nasdaq 2,870.99 +33.46 1.18%
Ticker Volume Price Price Delta
STOXX 50 2,136.90 -23.41 -1.08%
FTSE 100 5,318.28 -72.86 -1.35%
DAX 6,333.47 -63.37 -0.99%
Ticker Volume Price Price Delta
Nikkei 8,633.19 -23.89 -0.28%
TOPIX 723.62 -3.41 -0.47%
Hang Seng 18,690.20 -365.24 -1.92%
Gold 1,549.10 -0.12%
EUR-USD 1.2439 -0.5077%
Nasdaq 2,870.99 +1.18%
DJIA 12,580.70 +1.01%
S&P 500 1,332.42 +1.11%
FTSE 100 5,318.28 -1.35%
STOXX 50 2,136.90 -1.08%
DAX 6,333.47 -0.99%
Oil (WTI) 89.63 -1.25%
U.S. 10-year 1.690% -0.055
BAC:US 7.44 +4.06%
FB:US 28.84 -9.62%
  • Exchange: NASDAQ GS
  • Sector: Consumer, Non-cyclical
  • Industry: Pharmaceuticals
  • Sub-Industry: Medical-Drugs

Vivus Inc

Add to Portfolio

VVUS:US

24.8900 USD 0.3000 1.22%

As of 20:10:00 ET on 05/29/2012.

Snapshot for Vivus Inc (VVUS)

Open: 24.6900 Day's Range: 24.2500 - 24.9800 Volume: 1,651,836 Bid: 24.8700
Previous Close: 24.5900 52wk Range: 6.1300 - 26.7500 1-Yr Rtn: +181.56% Ask: 24.8800

Stock Chart for VVUS

No chart data available.
  • VVUS:US 24.8900
  • 1D
  • 1M
  • 1Y
24.5900
Interactive VVUS Chart

Previous Close

Key Statistics for VVUS

Current P/E Ratio (ttm) -
Estimated P/E (12/2012) -
Earnings Per Share (USD) (ttm) -0.5800
Est. EPS (USD) (12/2012) -0.6780
Est. PEG Ratio -
Market Cap (M USD) 2,481.56
Shares Outstanding (M) 99.70
Enterprise Value (M USD) (ttm) 2,148.16
Enterprise Value/EBITDA (ttm) -
Price/Book (mrq) 7.6200
Price/Sale (ttm) -
Dividend Indicated Gross Yield 0.0000
Next Earnings Announcement 08/01/2012
More VVUS Key Statistics mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Financials for VVUS

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)
More VVUS Income Statement Data
  • Total Assets
  • Total Liabilities (M/USD)
  • Debt to Assets (%)
More VVUS Balance Sheet Data
  • Operating
  • Investing
  • Financing (M/USD)
More VVUS Cash Flow Data

Company Profile & Key Executives for VVUS

VIVUS, Inc. is a biopharmaceutical company developing therapies for obesity, sleep apnea, diabetes and sexual health. The company markets a treatment for erectile dysfunction, and has drugs for obesity and erectile dysfunction in late-stage clinical trials.

Mark B LoganChairmanLeland F WilsonChief Executive Officer
Peter Y TamPresidentTimothy E MorrisSenior VP:Finance/CFO/Secy
More Company Profile & Key Executives for VVUS

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Advertisement
Advertisement
Advertisements